Dyne Therapeutics Inc. (NASDAQ: DYN) stands out as one of the best stocks to buy under $20.

On September 29, Dyne Therapeutics announced a significant milestone: Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation for its investigational therapeutic, DYNE-251.

This designation targets individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to treatment with DYNE-251.

The Orphan Drug status is a crucial step in the development of DYNE-251, potentially providing benefits such as market exclusivity and regulatory assistance, which can accelerate the availability of this promising therapy for patients in need.

Investors and stakeholders will be closely watching Dyne Therapeutics as it advances its pipeline and seeks to address unmet medical needs in the muscular dystrophy community.
https://ca.finance.yahoo.com/news/dyne-investigational-dmd-drug-dyne-205457972.html